Groundbreaking research has led to a novel model using human induced pluripotent stem cell (iPSC)-derived cortical neurons to understand Alzheimer’s disease (AD). This model accurately reproduces key aspects of aging in a microphysiological system, offering a valuable tool for drug discovery and disease study.
AD affects millions, and current treatments provide limited relief. The team addressed a challenge in AD research by studying the degeneration of cortical layers associated with cognitive decline. Their MPS system effectively captured this aspect, revealing how cellular aging contributes to disease progression and therapy resistance.
The model allowed researchers to measure neuronal activity and aging biomarkers in real time, facilitating drug screening and potential therapeutic development. It also uncovered complex disease mechanisms, such as the role of inflammation in neuronal senescence. By treating the neurons with amyloid-β, a key player in AD development, they mimicked disease pathophysiology and analyzed senescence and therapeutic responses.
The study highlights the model’s accuracy in recapitulating AD hallmarks, showcasing its potential for translational research. It offers a novel approach to accelerate drug discovery and regulatory submissions for new AD treatments. By integrating neuronal function with proteome responses, the platform promises to advance the understanding of AD and other neurological disorders.
This groundbreaking model provides an invaluable tool for researchers to delve deeper into AD pathophysiology and explore new therapeutic avenues, offering hope for patients affected by this devastating condition.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
